---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Limitations of current therapies"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Limitations of current therapies. Topics: Summary: antihistamine-refractory and uncontrolled disease; Summary: response and nonresponse to omalizumab; Summary: response and nonresponse to dupilumab and remibrutinib; Summary: ciclosporin and systemic corticosteroid harms, cost, and preferences; 12 further topics. 16 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Limitations of current therapies

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

### Summary: antihistamine-refractory and uncontrolled disease

- Updosing: in a meta-analysis, 63·2% (95% CI 57 to 69·6) of participants with CSU who did not respond to a standard antihistamine dose responded to updosing; the authors state that study weakness and heterogeneity made a final conclusion difficult. A dose-response network meta-analysis of 211 trials (22,187 participants) suggested that there may be diminishing additional benefit beyond standard dosing (8 more per 100 participants improving by a minimal important difference with a double dose and 16 more with a quadruple dose).
- Real-world control: in the AWARE study, sponsored by the manufacturer of omalizumab, uncontrolled CSU (UCT below 12) at Month 24 was reported in 23.2% (26 of 112) of participants on non-sedating H1-antihistamines, 41.9% (44 of 105) on updosed non-sedating H1-antihistamines, and 27.1% (78 of 288) on omalizumab.
- US claims: proxy events for uncontrolled CSU (prescriptions for corticosteroids, biologics, or immunosuppressants, or CSU-related inpatient, emergency department, or urgent care visits) occurred in 59.1% of adults with diagnosed CSU, and, excluding over-the-counter medication and antihistamines, corticosteroids were the most prescribed treatment after diagnosis (78.3% of 200,298 adults; 68.2% systemic).

Source: [Guillén-Aguinaga et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27237730/); [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030); [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/); [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/); [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.2.1.7-2"></a>

### Summary: response and nonresponse to omalizumab

- Week 12 response: in CSU Trial 1 of the label, UAS7=0 was reported in 36% with omalizumab 300 mg and 9% with placebo. In participants symptomatic despite H1-antihistamines at up to 4 times the approved dose plus H2-antihistamines or leukotriene receptor antagonists, UAS7 of 6 or less was reached by 132 (52.4%) with omalizumab 300 mg and 10 (12.0%) with placebo, and UAS7 = 0 by 85 (33.7%) and 4 (4.8%).
- Insufficient response: the international guideline states that omalizumab at higher doses, shorter intervals, or both is off-label. Nonrandomized data (n = 149) suggest that 69% (95% CI 59% to 78%) of patients refractory to standard-dose omalizumab may respond with higher doses or more frequent administration. Type IIb autoimmune CSU is characterized by poor response to antihistamines and to omalizumab.
- Persistence: in a meta-analysis of 8 observational studies (4516 participants), median omalizumab drug survival was 3.1 years, 7-year survival was 30% in CSU alone, and autoimmune comorbidity was associated with discontinuation for lack of efficacy (HR 2.03; 95% CI 1.20 to 3.41).
- Safety: the label estimates anaphylaxis in at least 0.2% of patients from postmarketing reports and directs that omalizumab be initiated only in a healthcare setting equipped to manage anaphylaxis.

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf); [Kaplan et al. (2013)](https://doi.org/10.1016/j.jaci.2013.05.013); [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004); [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010); [Altayf et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42714921/)

<a id="topic-2.2.2.1.7-3"></a>

### Summary: response and nonresponse to dupilumab and remibrutinib

- Dupilumab: in anti-IgE-naive participants, UAS7 = 0 at Week 24 was reported in 22 (32.4%) with dupilumab and 9 (13.2%) with placebo in CUPID Study A, and in 22 (30.1%) and 13 (17.3%) in Study C. CUPID Study B, in 108 participants who were inadequate responders to or intolerant of anti-IgE treatment, did not meet its primary endpoint (ISS7 at Week 24). The international guideline states that dupilumab efficacy is likely to be less pronounced than that of omalizumab, and a network meta-analysis states that its impact on quality of life is uncertain and that no dupilumab trial addressed angioedema activity.
- Remibrutinib: at Week 12, UAS7 = 0 was reported in 96 (31.1%) with remibrutinib and 16 (10.5%) with placebo in REMIX-1, and in 83 (27.9%) and 10 (6.5%) in REMIX-2. The label reports bleeding in 9% of patients treated with remibrutinib and 2% with placebo over the 24-week controlled period, requires interruption for 3 to 7 days before and after surgery, and advises avoiding use with strong or moderate CYP3A4 inhibitors or inducers and in hepatic impairment (Child-Pugh A, B, and C); safety and effectiveness have not been established in pediatric patients. The network meta-analysis commissioned for the US guideline states that the safety profile of remibrutinib is less certain.

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf); [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004); [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

### Summary: ciclosporin and systemic corticosteroid harms, cost, and preferences

- Ciclosporin is off-label for urticaria and the international guideline recommends it only for severe disease refractory to licensed treatments. In a meta-analysis of 18 studies (909 participants), response to low to moderate doses was 54%, 66%, and 73% at 4, 8, and 12 weeks, and 6%, 23%, and 57% of participants on very low, low, and moderate doses had 1 or more adverse events. The guideline states that ciclosporin is embryotoxic in animal models and associated with preterm delivery and low birth weight.
- The international guideline recommends against long-term systemic corticosteroids and suggests a rescue course of up to 10 days for acute exacerbations. In US claims, the 10 most common adverse events after systemic corticosteroid initiation, including hypertension, lipid disorders, diabetes, and cataracts, occurred in higher proportions of corticosteroid users than non-users, and the proportion with adverse events generally increased with longer use.
- The international guideline acknowledges that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost and that ciclosporin is restricted by its safety profile. Across 18 studies of patient values and preferences (28,497 participants), oral or topical treatments were favored over injections and infusions were least favored (moderate certainty).

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/); [Kulthanan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916431/); [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/); [Chu et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/41060663/)

<a id="topic-2.2.2.1.7-5"></a>

### Response to updosed antihistamines in non-responders to standard doses: meta-analysis

> “We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.”
> “The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).”
> “However, the relative weakness of the studies and the significant heterogeneity among them made it difficult to reach a final conclusion.”

Source: [Guillén-Aguinaga et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27237730/)

<a id="topic-2.2.2.1.7-6"></a>

### Uncontrolled CSU at Month 24 on antihistamines and on omalizumab: AWARE, sponsored by the manufacturer of omalizumab

> “AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.”
> “The proportion of patients with uncontrolled CSU (UCT score <12) dropped from 78% (n/N = 1641/2104) at baseline to 28.7% (n/N = 269/936) after two years of participation in the AWARE study.”
> “Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.”
> “Further studies are needed to understand the differences between guideline recommendations and reported management.”

Source: [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/)

<a id="topic-2.2.2.1.7-7"></a>

### Uncontrolled CSU among treated participants in a US claims cohort

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Proxy events representing uncontrolled CSU (any record of prescriptions for corticosteroids, biologics, or immunosuppressants [excluding all antihistamines and over-the-counter medication] or any CSU-related inpatient admissions or emergency department or urgent care visits) were used to identify patients with uncontrolled CSU.”
> “Proxy events were observed in 59.1% of the patients.”
> “Of patients with CSU who were prescribed treatment, more than 50% experienced uncontrolled CSU, which was associated with increased HCRU and health care costs.”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.2.1.7-8"></a>

### Insufficient response to licensed-dose omalizumab and off-label updosing

> “Patients with urticaria who do not show sufficient benefit from treatment with omalizumab at the licensed dose of 300 mg every 4 weeks can be treated with omalizumab at higher doses, shorter intervals, or both.”
> “Patients need to be informed that omalizumab updosing is off‐label.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.7-9"></a>

### Type IIb autoimmune CSU: poor response to antihistamines and omalizumab

> “Despite omalizumab’s high efficacy, a significant proportion of patients require third-line treatment, which, at present, is limited to cyclosporine”
> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti–thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

<a id="topic-2.2.2.1.7-10"></a>

### Dupilumab in participants symptomatic despite anti-IgE treatment: CUPID Study B did not meet the primary endpoint

> “while CUPID Study B included patients who remained symptomatic despite H1 antihistamine and anti-IgE treatments.”
> “The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.”

Source: [Dupixent prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s074lbl.pdf)

<a id="topic-2.2.2.1.7-11"></a>

### Omalizumab: anaphylaxis boxed warning and initiation in a healthcare setting

> “Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR.”
> “In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006.”
> “Initiate XOLAIR only in a healthcare setting equipped to manage anaphylaxis”

Source: [Xolair prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf)

<a id="topic-2.2.2.1.7-12"></a>

### Remibrutinib: bleeding and interruption around surgery

> “In clinical trials, mucocutaneous-related bleeding occurred in 9% of patients who received RHAPSIDO”
> “Interrupt treatment with RHAPSIDO for 3 to 7 days pre- and post-surgery or invasive procedures”

Source: [Rhapsido prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218436s001lbl.pdf)

<a id="topic-2.2.2.1.7-13"></a>

### Cost and safety restrictions on advanced therapies and ciclosporin in the international guideline

> “alternative treatments are needed for the remaining unresponsive patients.”
> “but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost, and that ciclosporin restricted due to its safety profile.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.7-14"></a>

### Ciclosporin and systemic corticosteroid harms

> “Adverse events appear to be dose dependent and occur in more than half the patients treated with moderate doses of CsA.”

Source: [Kulthanan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916431/)

> “The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use.”

Source: [Yosipovitch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13493736/)

<a id="topic-2.2.2.1.7-15"></a>

### Patient values and preferences: oral treatments favored over injections

> “The search resulted in 18 studies addressing the values and preferences among 28 497 participants.”
> “Moderate certainty evidence showed that patients were likely to place a high value on rapid improvement (eg, 2 days to 2 weeks) of disease signs and symptoms, long-term effectiveness, and treatments that were easy to prepare, use, and self-manage-oral or topical treatments were favored over injections, with the least favored being infusions.”

Source: [Chu et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/41060663/)

<a id="topic-2.2.2.1.7-16"></a>

### Omalizumab drug survival and discontinuation for lack of efficacy

> “The median drug survival for omalizumab was 3.1 years (95% CI, 2.8-3.4).”
> “Long-term drug survival appeared higher in chronic inducible urticaria (with or without concomitant CSU) than in CSU alone (7-year survival, 43%-49% vs 30%).”
> “Autoimmune comorbidity was associated with a higher risk of discontinuation due to lack of efficacy (HR, 2.03; 95% CI, 1.20-3.41)”

Source: [Altayf et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42714921/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
